Achaogen — JP Morgan Healthcare Conference 2018
23 slides from Achaogen's conference presentation, Jan 11, 2018

Slide 1: Corporate Presentation – JP Morgan Healthcare Conference
Corporate Presentation Nasdaq: AKAO JP Morgan Healthcare Conference Blake Wise CEO January 11, 2018

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operational and financial results and positions, business strategy, prospective products, p

Slide 3: Achaogen: Innovative Products for Serious Infections
Achaogen: Innovative Products for Serious Infections Large and growing patient populations Strong physician interest Value-based pricing potential Significant Commercial Opportunity Committed to addressing the urgent threat posed by multi-drug resistant (MDR) bacterial infections Pipeline of innovat

Slide 4: Multi-Drug Resistance Poses an Urgent and Growing Threat
Multi-Drug Resistance Poses an Urgent and Growing Threat Resistance rising rapidly2 High morbidity and mortality (up to 50% in BSI due to CRE)1,3 Limited treatment options4 Significant economic burden to healthcare system & society5 © Achaogen, Inc. All rights reserved. CDC Urgent1 CDC Serious1 Prio

Slide 5: There is a Demand for New Therapies to Fight MDR Infections
There is a Demand for New Therapies to Fight MDR Infections © Achaogen, Inc. All rights reserved. 1Diagn Microbiol Infect Dis 2016, http://dx.doi.org/10.1016/j.diagmicrobio.2016.04.022 E.coli is the causative pathogen in 79% of complicated UTI (incl. pyelonephritis): Lancet 2015;385:1949. 2.Source:

Slide 6: Pipeline to Address the Serious Threat of Antibiotic Resistance
CRE: carbapenem-resistant Enterobacteriaceae MDR: multi-drug resistant Pipeline to Address the Serious Threat of Antibiotic Resistance Program Preclinical Phase 1 Phase 2 Phase 3 Registration All product candidates are investigational only, potential treatments, and have not been approved for commer

Slide 7: Plazomicin Has Potent Activity Against MDR Enterobacteriaceae
Plazomicin has Potent Activity Against MDR Enterobacteriaceae, Including ESBL-Producers, CRE Strains and AG-Resistant Isolates Plazomicin: A Next Generation Aminoglycoside for the Potential Treatment of MDR Enterobacteriaceae Discovered at Achaogen; US patent protection currently estimated 2030-2032

Slide 8: Plazomicin Results Demonstrate Unique Clinical Profile
Plazomicin Results Demonstrate Unique Clinical Profile Reported positive results in two Phase 3 clinical trials, NDA submitted Phase 3 registration trial (vs. meropenem) 609 patients enrolled Achieved FDA and EMA-specified primary efficacy endpoints Lower relapse rate at Late Follow-Up in plazomicin

Slide 9: Positive Efficacy Results in EPIC Phase 3 Trial in cUTI/AP
Positive Efficacy Results in EPIC Phase 3 Trial in cUTI/AP Plazomicin demonstrated non-inferiority on FDA endpoint and statistical superiority to meropenem on EMA endpoints * lower bound of the CI exceeds zero indicating statistical superiority TOC: Test-of-Cure visit Composite Cure includes microbi

Slide 10: CARE Efficacy Results: BSI
CARE Efficacy Results: BSI Reduced mortality at Day 28 for plazomicin versus colistin in BSI Two-sided 90% CI calculated based on the unconditional exact method. Plazomicin Colistin 2/14 8/15 1/14 6/15 39.0% (9.4 to 65.5) 32.9% (4.0 to 60.1) BSI Subset (mMITT Population) Difference (colistin minus p

Slide 11: Plazomicin is Uniquely Positioned to Succeed in CRE and High-Risk cUTI Markets
Plazomicin is Uniquely Positioned to Succeed in CRE and High-Risk cUTI Markets Compelling Phase 3 Data – Survival benefit in CRE, sustained efficacy in cUTI Potential Label – NDA includes potential indications in both cUTI and BSI Differentiated Class – Only aminoglycoside amongst new market entrant

Slide 12: Significant Growth in Confirmed CRE Cases in the U.S.
Significant Growth in Confirmed CRE Cases in the U.S. with Approximately 70K to 80K Cases in 2016 and Trending Upwards Sources: Literature-based projection: Literature review combined with surveillance network data EHR-based projection: Analysis of Cerner Health Facts EHR database from ~200 hospital

Slide 13: Opportunity Can Be Captured With Efficient Commercial Model
Opportunity can be Captured With Efficient Commercial Model Given Concentration of CRE Source: IMS DDD, 2015-2016; IMS HCOS 2016 1 meropenem, imipenem and doripenem 2 Avycaz & Colistin Use Widespread Carbapenem Use1 Concentrated Use of CRE Drugs2 © Achaogen, Inc. All rights reserved. Achaogen Needs

Slide 14: Plazomicin Potential Approval and Launch Dates in 2018 Remain Base Case
Plazomicin Potential Approval and Launch Dates in 2018 Remain Base Case Plazomicin Drug Product Regulatory Overview Assumed facility for plazomicin launch continues to be Pfizer-McPherson © Achaogen, Inc. All rights reserved. Form 483 is a form used by the FDA to document and communicate concerns di

Slide 15: C-Scape: Oral Antibiotic Candidate for cUTI
C-Scape: Oral Antibiotic Candidate for cUTI © Achaogen, Inc. All rights reserved.

Slide 16: C-Scape Executive Summary
C-Scape Executive Summary Oral antibiotic to treat infections due to ESBL-producing Enterobacteriaceae WHO: Critical Priority 1 Pathogen CDC: Serious Public Health Threat Higher probability of clinical and regulatory success given history of use of individual components Compelling commercial opportu

Slide 17: C-Scape is a Uniquely Potent β-lactam / β-lactamase Inhibitor Combination
Organism ESBL Enzyme Amoxicillin-Clavulanate MIC (µg/mL) Ciprofloxacin MIC (µg/mL) C-Scape MIC (µg/mL) E. coli CTX-M-15,TEM-1 16 ≤0.03 0.5 E. coli CTX-M-15,TEM-1 8 >4 0.5 E. coli CTX-M-14 8 ≤0.03 0.5 K. pneumoniae SHV-5,TEM-1 8 0.25 0.12 K. pneumoniae SHV WT,CTX-M-15, OXA-1/30-like 16 1 0.5 K. pneum

Slide 18: C-Scape Shows Potency Against ESBL-Producing Enterobacteriaceae
C-Scape Shows Potency Against ESBL-Producing Enterobacteriaceae Cumulative Percent of Isolates MIC (μg/mL) C-Scape MIC90 = 1 μg/mL in ESBL-Producing Enterobacteriaceae 379 E. coli or K. pneumoniae from US & EU (2014-15) genotyped for CTX-M, TEM or SHV ESBLs © Achaogen, Inc. All rights reserved.

Slide 19: Clavulanate Restores the Efficacy of Ceftibuten Against Target Pathogens
Clavulanate Restores the Efficacy of Ceftibuten Against Target Pathogens © Achaogen, Inc. All rights reserved. hours 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 Vehicle Ceftibuten Ceftibuten+Clavulanate Ceftibuten Ceftibuten+Clavulanate Vehicle Log10 CFU Change Log10 CFU 24 Hours ESBL-Producing E. coli

Slide 20: C-Scape Phase 1 Top-Line Results
C-Scape Phase 1 Top-Line Results The combination of ceftibuten/clavulanate was well tolerated when administered for 14 days across all dosing regimens tested No serious adverse events (SAEs), grade 3 or 4 adverse events, or adverse events leading to discontinuation of study drug were observed Safety

Slide 21: C-Scape Addresses a Large and Growing Patient Population
C-Scape Addresses a Large and Growing Patient Population With Strong Physician Interest in Product Profile Sources: Decision Resources, Arlington Medical Resources, primary literature, CDC, TSN Surveillance Network, TEST Surveillance Database, and company internal analysis NVC Consulting Qual/Quant

Slide 22: Financial Snapshot
Financial Snapshot $199.4 million in cash, cash equivalents, short-term investments at 9/30/17 Additional restricted cash of $10.7 million associated with Gates Foundation partnership at 9/30/17 Funding partnerships BARDA non-dilutive funding of $124.3 million for plazomicin development BARDA non-di

Slide 23: Significant Progress & Strong Execution
2017 2018 ü Significant Progress & Strong Execution Multiple Drug Candidates to to Address Significant Patient Need ü Plazomicin NDA submission C-Scape Ph 1 results Advance C-Scape to Ph 3 Plazomicin commercial launch Plazomicin FDA action June 25 Plazomicin MAA submission ü Plazomicin NDA accepted
Source: SEC EDGAR · 8-K filed Jan 11, 2018


